Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow

D E Hughes, B R MacDonald, R G Russell, M Gowen, D E Hughes, B R MacDonald, R G Russell, M Gowen

Abstract

Bisphosphonates inhibit bone resorption in vivo and in vitro by unknown mechanisms. The effect of bisphosphonates on the formation of osteoclasts from their mononuclear hematopoietic precursors was investigated using human long-term marrow cultures in which multinucleated cells form that express most of the known features of the osteoclast phenotype (e.g., bone resorption, tartrate-resistant acid phosphatase, calcitonin responsiveness, and reactivity with specific MAbs). The five bisphosphonates that were tested strongly inhibited 1,25-dihydroxyvitamin D3-stimulated formation of these cells with the same relative potencies as they inhibit bone resorption in vivo. Two representative compounds (3-amino-1-hydroxypropylidene-1,1-bisphosphonate and dichloromethylene bisphosphonate) failed to inhibit the proliferation of precursors of the osteoclast-like cells. However, these compounds decreased the proportion of mononuclear and multinucleated cells expressing an osteoclast antigen, thus suggesting a degree of specificity for cells of the osteoclast lineage. We conclude that bisphosphonates are potent inhibitors of osteoclast-like cell formation in long-term human marrow cultures, and that this may be related to their ability to inhibit bone resorption in vivo.

References

    1. Lancet. 1980 May 17;1(8177):1043-7
    1. J Immunol Methods. 1983 Dec 16;65(1-2):55-63
    1. J Histochem Cytochem. 1984 Feb;32(2):219-29
    1. Br J Cancer. 1985 May;51(5):665-9
    1. Clin Sci (Lond). 1985 Oct;69(4):403-11
    1. Cancer Res. 1985 Nov;45(11 Pt 2):5663-9
    1. Lancet. 1985 Oct 26;2(8461):907-10
    1. Am J Pathol. 1986 Feb;122(2):363-78
    1. Calcif Tissue Int. 1986 Apr;38(4):227-33
    1. J Clin Invest. 1986 Oct;78(4):894-8
    1. J Immunol. 1986 Dec 1;137(11):3544-9
    1. Endocrinology. 1987 Jun;120(6):2326-33
    1. J Cell Physiol. 1987 Sep;132(3):441-52
    1. J Bone Miner Res. 1987 Apr;2(2):135-42
    1. J Bone Miner Res. 1986 Apr;1(2):227-33
    1. Bone Miner. 1987 Feb;2(1):29-42
    1. Bone Miner. 1986 Feb;1(1):27-39
    1. Bone Miner. 1986 Apr;1(2):127-35
    1. Anat Rec. 1962 Aug;143:329-37
    1. N Engl J Med. 1973 Dec 27;289(26):1379-84
    1. Lancet. 1974 May 11;1(7863):894-8
    1. Neth J Med. 1974;17(6):281-98
    1. Nature. 1975 Nov 27;258(5533):325-7
    1. J Clin Endocrinol Metab. 1977 Jan;44(1):96-106
    1. Ann Intern Med. 1977 Dec;87(6):656-63
    1. Blood. 1978 Mar;51(3):507-19
    1. Biochem J. 1978 Apr 15;172(1):97-107
    1. Lancet. 1979 Apr 14;1(8120):799-803
    1. Nature. 1980 Feb 14;283(5748):669-70
    1. J Clin Invest. 1981 Oct;68(4):1086-92
    1. J Clin Invest. 1982 Nov;70(5):927-33
    1. Lancet. 1983 Jul 30;2(8344):239-43
    1. Blood. 1981 Sep;58(3):630-41

Source: PubMed

3
Abonner